Section 4: Clinical Pharmacy Services

4CPS-046

PHARMACEUTICAL INTERVENTIONS IN ANTIMICROBIAL TREATMENT IN A 150-BED HOSPITAL

4CPS-045

VALUE OF THE CLINICAL PHARMACIST IN THE PHARMACOKINETIC MONITORING OF ANTIMICROBIALS: HEALTH OUTCOMES

4CPS-044

IMPACT OF CLINICAL PHARMACIST-VANCOMYCIN MONITORING ON PATIENT SAFETY OUTCOME

4CPS-043

EXTENSIVELY PANDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS: ANALYSIS AND OUTCOMES

4CPS-042

SWITCH FROM CLARITHROMYCIN TO AZITHROMYCIN - ONE OPTION TO OPTIMISE MACROLIDE USE THROUGH CLINICAL PHARMACISTS

4CPS-041

IMPLEMENTATION OF AN EMPIRICAL ANTIBIOTIC TREATMENT GUIDE: IMPACT ON ANTIOBITIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT

4CPS-040

OPTIMISING OF ANTIBIOTIC PROPHYLAXIS AT CARDIAC SURGERY CLINIC

4CPS-039

DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT

4CPS-038

QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB

4CPS-037

THE IMPACT OF MULTIDISCIPLINARY COLLABORATION IN OPTIMISING THE PRESCRIPTION OF ANTIBIOTICS IN A PAEDIATRIC HOSPITAL

4CPS-036

APREMILAST ADHERENCE IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS

4CPS-035

PERSISTENCE AND SAFETY OF APREMILAST IN PSORIASIS

4CPS-034

USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS

4CPS-033

THE USE OF ORAL APREMILAST FOR THE TREATMENT OF PLAQUE PSORIASIS

4CPS-032

SKIN PROTECTION AND PREVENTION OF CUTANEOUS MYCOSIS

Pages